In cardiometabolic contexts such as DM2 and HTN, agents like SGLT2 inhibitors and AMPK/Sirtuin modulators illustrate how metabolic correction can dovetail with oxidative protection. The gene discussed is SLC5A2; the disease is hypertensive disorder.